文献速递眼底病与葡萄膜炎

容忍视网膜下液治疗新生血管性年龄相关性黄斑变性:FLUID研究24个月结果

Tolerating Subretinal Fluid in Neovascular Age-Related Macular Degeneration Treated with Ranibizumab Using a Treat-and-Extend Regimen: FLUID Study 24-Month Results.
PubMed 文献 · Ophthalmology · 2018-11-29

FLUID研究是一项多中心随机24个月4期单盲非劣效性临床试验,比较雷珠单抗治疗新生血管性年龄相关性黄斑变性时容忍部分视网膜下液(SRF)与完全消除SRF的疗效。结果显示容忍SRF组(仅当中心凹SRF>200μm时才处理)视力获益非劣效于完全消除组,且注射次数更少。

要点

  • 容忍部分SRF(中心凹中心≤200μm)的视力获益非劣效于完全消除SRF。
  • 容忍SRF组24个月平均注射次数更少(15.8次 vs 17次)。
  • 容忍SRF组更多患者延长至并维持12周治疗间隔。

核心结论

  • 采用雷珠单抗T&E方案治疗nAMD时,容忍部分SRF可达到与完全消除SRF相当的视力结局,且注射次数更少。

研究设计与样本

  • 多中心、随机、24个月、4期、单盲、非劣效性临床试验,纳入349例初治活动性中心凹下CNV患者,随机分为强化组(n=174)和放松组(n=175)。
  • 强化组每月注射至SRF和IRF完全消退,放松组每月注射至所有IRF消退(中心凹中心SRF>200μm除外)后再延长间隔。
  • 主要终点为24个月BCVA平均变化,采用5字母非劣效性界值;279例(79.9%)完成24个月随访。

主要发现

  • 24个月BCVA平均变化:强化组3.0字母(SD 16.3),放松组2.6字母(SD 16.3),放松组非劣效于强化组(P=0.99)。
  • 两组达到20/40或更好视力的比例分别为53.5%和56.6%(P=0.92),达到20/200或更差视力的比例分别为8.7%和8.1%(P=0.52)。
  • 放松组24个月平均注射次数为15.8次(SD 5.9),少于强化组的17次(SD 6.5)(P=0.001)。
  • 强化组从未延长超过4周间隔的患者比例(13.5%)显著高于放松组(2.8%)(P=0.003);放松组延长至并维持12周间隔的患者比例(29.6%)显著高于强化组(15.0%)(P=0.005)。

关键数值与推荐

  • 放松组容忍中心凹中心≤200μm的SRF,仅当SRF>200μm时才要求消除。
  • 非劣效性界值为5字母。
  • 主要终点为24个月BCVA平均变化。

临床怎么用

  • 在雷珠单抗T&E方案中,可考虑容忍中心凹中心≤200μm的SRF,以减少注射次数并延长治疗间隔,同时维持视力获益。

局限性

  • 24个月随访完成率为79.9%,存在失访偏倚可能。
  • 研究纳入初治活动性中心凹下CNV患者,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To test the hypothesis that tolerating some subretinal fluid (SRF) in patients with neovascular age-related macular degeneration (nAMD) treated with ranibizumab using a treat-and-extend (T&E) regimen can achieve similar visual acuity (VA) outcomes as treatment aimed at resolving all SRF. DESIGN: Multicenter, randomized, 24-month, phase 4, single-masked, noninferiority clinical trial. PARTICIPANTS: Participants with treatment-naïve active subfoveal choroidal neovascularization (CNV). METHODS: Participants were randomized to receive ranibizumab 0.5 mg monthly until either complete resolution of SRF and intraretinal fluid (IRF; intensive arm: SRF intolerant) or resolution of all IRF only (relaxed arm: SRF tolerant except for SRF >200 μm at the foveal center) before extending treatment intervals. A 5-letter noninferiority margin was applied to the primary outcome. MAIN OUTCOME MEASURES: Mean change in best-corrected VA (BCVA), and central subfield thickness and number of injections from baseline to month 24. RESULTS: Of the 349 participants randomized (intensive arm, n = 174; relaxed arm, n = 175), 279 (79.9%) completed the month 24. The mean change in BCVA from baseline to month 24 was 3.0 letters (standard deviation, 16.3 letters) in the intensive group and 2.6 letters (standard deviation, 16.3 letters) in the relaxed group, demonstrating noninferiority of the relaxed compared with the intensive treatment (P = 0.99). Similar proportions of both groups achieved 20/40 or better VA (53.5% and 56.6%, respectively; P = 0.92) and 20/200 or worse VA (8.7% and 8.1%, respectively; P = 0.52). Participants in the relaxed group received fewer ranibizumab injections over 24 months (mean, 15.8 [standard deviation, 5.9]) than those in the intensive group (mean, 17 [standard deviation, 6.5]; P = 0.001). Significantly more participants in the intensive group never extended beyond 4-week treatment intervals (13.5%) than in the relaxed group (2.8%; P = 0.003), and significantly more participants in the relaxed group extended to and maintained 12-week treatment intervals (29.6%) than the intensive group (15.0%; P = 0.005). CONCLUSIONS: Patients treated with a ranibizumab T&E protocol who tolerated some SRF achieved VA that is comparable, with fewer injections, with that achieved when treatment aimed to resolve all SRF completely.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Guymer RH, Markey CM, McAllister IL, et al. Tolerating Subretinal Fluid in Neovascular Age-Related Macular Degeneration Treated with Ranibizumab Using a Treat-and-Extend Regimen: FLUID Study 24-Month Results. Ophthalmology. 2018. PMID: 30502372. doi:10.1016/j.ophtha.2018.11.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。